The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy-letter

Leon, L. G. and Funel, N. and Peters, G. J. and Avan, A. and Vistoli, F. and Boggi, U. and Giovannetti, E. (2016) The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy-letter. Clinical Cancer Research, 22 (10). p. 2594.

[img] Text
2594.full.pdf

Download (138kB)
Item Type: Article
Additional Information: Export Date: 16 February 2020 CODEN: CCREF Correspondence Address: Giovannetti, E.; Cancer Pharmacology Lab, AIRC Start-UP Unit, University of PisaItaly; email: elisa.giovannetti@gmail.com
Uncontrolled Keywords: gemcitabine pimasertib protein kinase B protein RRM1 ribonucleotide reductase unclassified drug deoxycytidine protein kinase inhibitor antineoplastic activity apoptosis cancer combination chemotherapy drug efficacy drug potentiation enzyme phosphorylation G1 phase cell cycle checkpoint gene gene mutation human Letter nonhuman oncogene K ras pancreas adenocarcinoma priority journal Rrm1 gene TP53 gene Humans Protein Kinase Inhibitors
Subjects: QU Biochemistry
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 02 Mar 2020 04:49
Last Modified: 02 Mar 2020 04:49
URI: http://eprints.mums.ac.ir/id/eprint/13072

Actions (login required)

View Item View Item